safety, data integrity, and regulatory compliance. Choosing the right site is a critical success factor. From facility readiness to investigator experience, this tutorial explores how to select, prepare, and equip clinical sites for conducting high-quality early-phase trials.

Why Site Selection Matters in Phase 1 Trials

Unlike later-phase trials that focus on large patient cohorts and therapeutic outcomes, Phase 1 studies demand intense monitoring, tight protocol adherence, and robust bioanalytical support. Site infrastructure and experience play a pivotal role in minimizing risk, avoiding protocol deviations, and producing reliable pharmacokinetic and safety data.

Key Criteria for Selecting a Phase 1 Clinical Site

1. Prior Experience with Early-Phase Research

• Has the site conducted first-in-human or SAD/MAD studies before?
• Does the site understand the unique demands of exploratory and PK-driven protocols?
• What is their track record with regulatory inspections and audits?

2. Qualified Investigators and Support Staff

• Principal Investigator (PI) with experience in early-phase risk management and AE reporting
• Sub-investigators with pharmacokinetic or imaging trial experience
• Dedicated study coordinators and research nurses for 24/7 monitoring
• In-house or affiliated pharmacologist, radiologist, and safety physician if required

3. Ethics Committee (EC/IRB) Accreditation

• Site must be linked to a registered and experienced Ethics Committee
• Preferably with experience reviewing FIH or high-risk studies

Core Infrastructure Requirements for Early-Phase Trials

1. Clinical Unit Facilities

• Overnight stay and observation rooms for in-patient monitoring (especially for SAD/MAD studies)
• Dedicated emergency crash cart and resuscitation equipment
• Quiet, controlled environments for ECGs, vitals, and cognitive assessments

2. Laboratory and Sample Handling Infrastructure

• On-site or rapid access to centrifuges, refrigerators (2–8°C), and ultra-low (-80°C) freezers
• Sample tracking, labeling, and chain-of-custody SOPs
• Validated bioanalytical lab partnership (on-site or courier-linked)

3. Drug Storage and Pharmacy Setup

• Secure, access-controlled IMP (Investigational Medicinal Product) storage area
• Temperature monitoring and calibration logs
• Trained pharmacist or IMP custodian familiar with handling blinded/randomized studies

4. Safety and Emergency Capabilities

• Emergency medical response team on standby or within rapid reach
• Access to hospital ICU within 30 minutes
• Protocols for unblinding and managing SAE in real time

Data Collection and Technology Readiness

• Validated EDC systems with real-time data entry capabilities
• Secure Wi-Fi and digital audit trail for remote monitoring or risk-based monitoring visits
• On-site document management for source documents, CRFs, consent forms

Site Feasibility Assessment Checklist

Before selecting a site, sponsors and CROs should use a detailed feasibility checklist including:

• Previous early-phase study experience (FIH, SAD/MAD)
• Subject recruitment performance and demographic match
• Availability of backup staff for continuity
• Understanding of GCP and early-phase SOPs
• Protocol-specific capabilities (e.g., imaging, biopsies, CSF collection)

Regulatory Compliance and Site Accreditation

• For India: Site must be listed in CDSCO records and have DCGI-approved ethics committee
• For the U.S.: Sites must follow 21 CFR Part 312 and have IRB accreditation
• For EU: Sites must be registered in the EudraCT and compliant with CTR regulations

Common Pitfalls in Site Selection

• Assuming all CRO-partnered sites are FIH-capable without audit
• Inadequate sample storage leading to invalid PK results
• Lack of 24-hour on-call physician for AE management
• Failure to assess training and GCP documentation of site staff

Case Example: Oncology Phase 1 Site Preparedness

For a Phase 1 dose-escalation trial of a novel oncology compound, the sponsor selected a site with built-in PET scan facility, 24-hour medical coverage, and in-house pharmacists. The site had successfully handled three FIH oncology studies in the past 24 months. Their ability to provide real-time AE reporting and PK sample transfer within 3 hours of collection led to high data integrity and faster decision-making across cohorts.

Best Practices for Sponsors and CROs

• Conduct site qualification visits (SQVs) at least 8 weeks before FPFV (First Patient First Visit)
• Provide clear protocol training and roles/responsibilities matrix
• Ensure parallel startup activities (regulatory, ethics, lab contracts) to save time
• Develop a contingency plan for key equipment or staff absences

Conclusion

Phase 1 clinical trials require a level of precision and preparedness that goes beyond standard site operations. Choosing a site with the right combination of infrastructure, trained personnel, safety readiness, and regulatory awareness is foundational to success. Whether working with a dedicated early-phase unit or a hospital-based research center, your site partner should be a true extension of your quality culture—ready to execute with speed, compliance, and confidence.